OPEN Research Support
head

Specialist registrar
Suganya Ganesalingam
Department of Medical Gastroenterology, Odense University Hospital


Projekt styring
Projekt status    Sampling ongoing
 
Data indsamlingsdatoer
Start 01.03.2016  
Slut 28.02.2030  
 



Gut And Liver axis in Healthy Population (GALA-HP)

Short summary

The study wishes to compare gut microbiota, host metabolic and gene expression in healthy, matched subjects to patients with liver disease of alcoholic and non-alcoholic etiology.


Rationale

We hypothesize that specific compositional and functional changes in the gut microbiota together with host metabolic and gene expression changes are key predictors for the development and progression of liver fibrosis, the precursor of cirrhosis, in alcohol overusing individuals and individuals with non-alcoholic fatty liver disease. To test the hypothesis, we need to compare changes in diseased individuals with a control cohort of healthy subjects.  

This project is part of the  GALAXY consortium (Gut-and-liver-axis in alcoholic liver fibrosis), which is exploring the role of the gut microbiome in alcoholic liver fibrosis to improve understanding, diagnosis, prevention and treatment of chronic liver disease. Additionally, the following projects are also a part of the GALAXY consortium:  OP_40 and  OP_80.


Description of the cohort

In GALA-HP we will establish a cross-sectional study at Odense University Hospital comprising 150 healthy individuals from the age 18-75, whom will be included over the next 24 months. 


Data and biological material

Pre-screening (duration: 5 min.)

  • Online Questionnaire
First inclusion visit (duration: 2 hours)
  • Weight and height
  • Heart rate, blood pressure and EKG
  • QoL and food frequency questionnaire (FFQ) and other baseline questions
  • Nutritional status, hand-grip strength, abdominal circumference bio impedance
  • Blood testing
  • Tissue sampling for biobank (blood, urine, sputum, stool)
  • Liver Stiffness measurement and abdominal ultrasound
Second inclusion visit (duration: 3-4 hours)
  • Sigmoidoscopy + biopsies
  • Magnetic resonance scan  


Collaborating researchers and departments

Department of Clinical Biochemistry and Pharmacology

  • Associate Professor Sönke Detlefsen
Novo Nordisk Center for Basic Metabolic Research
  • Professor Torben Hansen

European Molecular Biology Laboratory, EMBL, University of Heidelberg, Germany

  • Postdoctoral fellow Shinichi Sunagawa

Academy of Athens, Greece

  • Consultant Foteini Christodoulou  

NNF Center for Protein Research, University of Copenhagen

  • Professor Matthias Mann

Steno Diabetes Centre A/S

  • Professor Matej Oresic

Nordic Biosciense A/S 

  • CEO and professor Morten Karsdal 

Laboratory for Fibrosis and Portal Hypertension, Department of Internal Medicine, University of Bonn, Germany

  • Associate Professor Jonel Trebicka 

Publications associated with the project

Describing the fecal metabolome in cryogenically collected samples from healthy participants. Trošt, K., Ahonen, L., Suvitaival, T.  et al.   Sci Rep 10, 885 (2020). https://doi.org/10.1038/s41598-020-57888-w